Marian Iwamoto

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
    Jacqueline B McCrea
    Merck Research Laboratories, Bluebell, PA 19422, USA
    Clin Pharmacol Ther 74:17-24. 2003
  2. pmc Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics
    Marian Iwamoto
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 53:1747-52. 2009
  3. doi request reprint Effects of omeprazole on plasma levels of raltegravir
    Marian Iwamoto
    Merck and Co, Whitehouse Station, Rahway, NJ 07065 0900, USA
    Clin Infect Dis 48:489-92. 2009
  4. doi request reprint Atazanavir modestly increases plasma levels of raltegravir in healthy subjects
    Marian Iwamoto
    Merck, Whitehouse Station, RY34 A500, PO Box 2000, Rahway, NJ 07065 0900, USA
    Clin Infect Dis 47:137-40. 2008
  5. doi request reprint Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval
    M Iwamoto
    Merck and Co, Inc, RY34 A500, PO Box 2000, Rahway, NJ 07065 0900, USA
    J Clin Pharmacol 48:726-33. 2008
  6. ncbi request reprint Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
    M Iwamoto
    Department of Clinical Pharmacology, Merck Research Laboratories, a division of Merck and Co, Inc, Whitehouse Station, NJ, USA
    Clin Pharmacol Ther 83:293-9. 2008
  7. pmc Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir
    Marian Iwamoto
    Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065 0900, USA
    Antimicrob Agents Chemother 52:4338-43. 2008
  8. pmc Lack of a significant drug interaction between raltegravir and tenofovir
    Larissa A Wenning
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 52:3253-8. 2008
  9. ncbi request reprint Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation
    Marian Iwamoto
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 48:209-14. 2008
  10. pmc Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women
    Matt S Anderson
    Merck Research Labs, Merck and Co, Inc, Whitehouse Station, NJ 07065 0900, USA
    Br J Clin Pharmacol 71:616-20. 2011

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
    Jacqueline B McCrea
    Merck Research Laboratories, Bluebell, PA 19422, USA
    Clin Pharmacol Ther 74:17-24. 2003
    ..The effects of aprepitant on the these 2 corticosteroids were evaluated...
  2. pmc Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics
    Marian Iwamoto
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 53:1747-52. 2009
    ..No adjustment in the dose of raltegravir is required for patients with mild or moderate hepatic or renal insufficiency...
  3. doi request reprint Effects of omeprazole on plasma levels of raltegravir
    Marian Iwamoto
    Merck and Co, Whitehouse Station, Rahway, NJ 07065 0900, USA
    Clin Infect Dis 48:489-92. 2009
    ..Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary...
  4. doi request reprint Atazanavir modestly increases plasma levels of raltegravir in healthy subjects
    Marian Iwamoto
    Merck, Whitehouse Station, RY34 A500, PO Box 2000, Rahway, NJ 07065 0900, USA
    Clin Infect Dis 47:137-40. 2008
    ..Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir...
  5. doi request reprint Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval
    M Iwamoto
    Merck and Co, Inc, RY34 A500, PO Box 2000, Rahway, NJ 07065 0900, USA
    J Clin Pharmacol 48:726-33. 2008
    ..Administration of a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. A single supratherapeutic dose design may be appropriate for crossover thorough QTc studies...
  6. ncbi request reprint Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
    M Iwamoto
    Department of Clinical Pharmacology, Merck Research Laboratories, a division of Merck and Co, Inc, Whitehouse Station, NJ, USA
    Clin Pharmacol Ther 83:293-9. 2008
    ....
  7. pmc Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir
    Marian Iwamoto
    Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065 0900, USA
    Antimicrob Agents Chemother 52:4338-43. 2008
    ..No dose adjustment is required for raltegravir with coadministration with ritonavir or efavirenz...
  8. pmc Lack of a significant drug interaction between raltegravir and tenofovir
    Larissa A Wenning
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 52:3253-8. 2008
    ..87, 0.90, and 0.77, respectively. Coadministration of raltegravir and TDF does not change the pharmacokinetics of either drug to a clinically meaningful degree. Raltegravir and TDF may be coadministered without dose adjustments...
  9. ncbi request reprint Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation
    Marian Iwamoto
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 48:209-14. 2008
    ....
  10. pmc Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women
    Matt S Anderson
    Merck Research Labs, Merck and Co, Inc, Whitehouse Station, NJ 07065 0900, USA
    Br J Clin Pharmacol 71:616-20. 2011
    ....
  11. pmc Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir
    William D Hanley
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 53:2752-5. 2009
    ..Although the RAL C(12) was decreased with TPV-RTV in this study, favorable efficacy data collected in phase III studies substantiate that TPV-RTV may be coadministered with RAL without dose adjustment...
  12. pmc Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects
    Matt S Anderson
    Department of Clinical Pharmacology, Merck and Co, Inc, RY34A 500, P O Box 2000, Rahway, NJ 07065, USA
    Antimicrob Agents Chemother 52:4228-32. 2008
    ..Coadministration of etravirine and raltegravir was generally well tolerated; the data suggest that no dose adjustment for either drug is necessary...
  13. pmc Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir
    Larissa A Wenning
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Antimicrob Agents Chemother 53:2852-6. 2009
    ..Coadministration of rifampin and raltegravir is not contraindicated; however, caution should be used, since raltegravir trough concentrations in the presence of rifampin are likely to be at the lower limit of clinical experience...
  14. doi request reprint The minimal impact of food on the pharmacokinetics of ridaforolimus
    Mark Stroh
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cancer Chemother Pharmacol 70:177-82. 2012
    ..This open-label, randomized, 3-period crossover study investigated the effect of food on the pharmacokinetics of ridaforolimus 40 mg as well as safety and tolerability of the study medication...
  15. doi request reprint Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor
    Diana M Brainard
    Merck Sharp and Dohme Corp, Whitehouse Station, New Jersey, USA
    J Clin Pharmacol 51:1376-402. 2011
    ....
  16. doi request reprint Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation
    Diana M Brainard
    Merck and Co, Inc, 126 E Lincoln Ave, P O Box 2000, Rahway, NJ 07065, USA
    J Clin Pharmacol 51:943-50. 2011
    ..80 (0.68-0.94); and GMR of time to maximal concentration (C(max)) and 90% CI was 1.39 (0.87-2.21). Overall, coadministration of rifabutin did not alter raltegravir pharmacokinetics to a clinically meaningful degree...
  17. doi request reprint Effect of raltegravir on the pharmacokinetics of methadone
    Matt S Anderson
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Clin Pharmacol 50:1461-6. 2010
    ..Coadministration of raltegravir and methadone is generally well tolerated. Raltegravir has no clinically meaningful effect on methadone pharmacokinetics. No dose adjustment is required for methadone when coadministered with raltegravir...
  18. doi request reprint Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium
    Bach Yen T Nguyen
    ISENTRESS Discovery and Development Team, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Ann N Y Acad Sci 1222:83-9. 2011
    ..Raltegravir represents an important addition to the current armamentarium for the treatment of HIV infection...
  19. ncbi request reprint Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme
    Kelem Kassahun
    Department of Drug Metabolism, WP75B 200, Merck Research Laboratories, P O Box 4, West Point, PA 19486, USA
    Drug Metab Dispos 35:1657-63. 2007
    ..Collectively, the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation...
  20. doi request reprint Emerging pharmacology: inhibitors of human immunodeficiency virus integration
    Daria Hazuda
    Merck Research Labs, West Point, Pennsylvania 19486, USA
    Annu Rev Pharmacol Toxicol 49:377-94. 2009
    ..In addition, available pharmacokinetic and drug interaction data for raltegravir and elvitegravir, the two integrase inhibitors that are the most advanced in clinical development to date, are reviewed...
  21. doi request reprint Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms
    L A Wenning
    Department of Drug Metabolism, Merck Research Laboratories, a division of Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Clin Pharmacol Ther 85:623-7. 2009
    ..This increase is not clinically significant, and therefore no dose adjustment of raltegravir is required for individuals with the UGT1A1*28/*28 genotype...
  22. doi request reprint The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
    Mark Stroh
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Cancer Chemother Pharmacol 69:1247-53. 2012
    ....
  23. doi request reprint Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor
    Marian Iwamoto
    Department of Project Leadership and Management, Merck Sharp and Dohme Corp a Subsidiary of Merck and Co, Inc, Whitehouse Station, NJ, USA
    Cancer Chemother Pharmacol 72:493-508. 2013
    ..This review summarizes the pharmacokinetic properties of vorinostat...
  24. ncbi request reprint A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
    Eric H Rubin
    The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 2681, USA
    Clin Cancer Res 12:7039-45. 2006
    ....